ArticleBreast cancer research : BCR2025
Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiotherapy for Ductal Carcinoma In Situ: Toxicity, Quality of Life, and Decisional Regret at a Tertiary Cancer Center.Cancers · 2026Article
- Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women.Breast cancer research : BCR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast ductal carcinoma in situ (DCIS), considered a non-obligate precursor to invasive breast cancer, has been widely studied; however, trends in death rate from DCIS remain undocumented.
methodsTo examine the trend in death rate from DCIS among women (age at death, 40 + years) in the US, we quantified annual percent changes (APCs) and average APCs in age-standardized death rates using the Surveillance, Epidemiology, and End Results Program (SEER) 8 incidence-based mortality database and Joinpoint regression. The trend was quantified from 2000 to 2021, capturing deaths among women diagnosed between 1975 and 2021 and allowing for a 25-year follow-back period before each death year. Additionally, we employed the SEER 12 to assess disparities in death rates from DCIS by race and ethnicity during 2017-2021, based on diagnoses from 1992-2021. Trends in death rates from invasive breast cancer were analysed similarly.
resultsDeath rate from DCIS increased by 2.43% annually (95% confidence interval [CI] = 1.34-3.54) from 2000-2015, and then plateaued, leading to an overall statistically non-significant increase from 2000-2021 (1.01% per year; 95%CI = -0.20-2.24). This trend was in stark contrast with an average of 1.61% annual decrease in death rates for invasive breast cancer (95%CI = -1.95 to -1.27). From 2016-2021, death rate from DCIS was 87% higher among non-Hispanic Black women than non-Hispanic White women (2.98 vs 1.60 per 100,000), a relatively larger disparity than the 39% estimated for death rate from invasive cancer (55.96 vs 40.28 per 100,000).
conclusionsDistinct epidemiologic patterns in death rates between DCIS and invasive breast cancer highlight important implications for understanding the natural history and management of these malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.